FILE – In this Feb. 26, 2019 file photo, Albert Bourla, chief executive officer of Pfizer, prepares to testify before the Senate Finance Committee hearing on drug prices, on Capitol Hill in Washington. (AP Photo/Pablo Martinez Monsivais, File)

OAN Newsroom
UPDATED 8:37 AM PT – Wednesday, December 9, 2020

Pfizer’s chief executive said he’s fully prepared to face the U.S. vaccine advisory panel later this week.

During a briefing Tuesday, Albert Bourla said he expects an “intense meeting” with the panel, but remains confident that the experts will approve of the company’s COVID-19 vaccine candidate.

The Pfizer-BioNtech preventative has already been distributed in small amounts across Britain, but some officials have raised concerns about the extensive care needed to transport the vaccine.

Nevertheless, the company’s CEO remains optimistic.

“…these are experts, they will ask a lot of questions. We have answers, we believe, to every question that they will ask and I think they will vote ‘yes’ given the strength of the data,” Bourla asserted. “And then, it is up to the FDA to conclude the process and give the advise.”

This comes after the FDA released documents detailing how the vaccine candidate has no new safety or efficacy issues.

Public Affairs

Sign Up for Our Newsletters

Get notified first!

You May Also Like

Newsom Recall Shows States Can Do More to Protect Constitutional Rights: Dr. Cordie Williams

It’s a ‘shot across the bow’ of politicians who would restrict civic…

Texas State Senate Passes Election Integrity Bill Targeting Mail-in Ballots

The Republican-led Texas state Senate passed a bill early on Thursday that…

What’s in the Georgia Election Bill?

Republicans in Georgia enacted a set of election reforms last month that…

Grassroots Rebellion Grows With New Calls to Ban Critical Race Theory from Military, Public Schools

Kevin O’Leary said he was “devastated” when he learned his former football…